35959-38-7

Basic information

• Product Name: 1-(5-amino-2,5-dideoxypentofuranosyl)pyrimidine-2,4(1H,3H)-dione
• Synonyms: 2,4(1H,3H)-pyrimidinedione, 1-(5-amino-2,5-dideoxypentofuranosyl)-
• CAS NO: 35959-38-7
• Molecular Formula: C₉H₁₃N₃O₄
• Molecular Weight: 227.2172
• Mol File: 35959-38-7.mol
• Article Data: 12

Chemical Properties

• Density: 1.466g/cm³
• Refractive Index: 1.601
• CAS DataBase Reference: 1-(5-amino-2,5-dideoxypentofuranosyl)pyrimidine-2,4(1H,3H)-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(5-amino-2,5-dideoxypentofuranosyl)pyrimidine-2,4(1H,3H)-dione(35959-38-7)
• EPA Substance Registry System: 1-(5-amino-2,5-dideoxypentofuranosyl)pyrimidine-2,4(1H,3H)-dione(35959-38-7)

Safety Data

• Hazardous Substances Data: 35959-38-7(Hazardous Substances Data)

Usage

Chemical class

Pyrimidines

Analog of

Nucleoside thymidine

Use

Chemotherapeutic agent

Cancer types treated

Leukemia and lymphoma

Mechanism of action

Interferes with DNA synthesis in cancer cells

Potential use

Antiviral therapy against certain viruses (e.g., HIV)

Research status

Further research needed to understand mechanisms of action and potential applications in medicine

Upstream product

• 1336-21-6 ammonium hydroxide 
• 35959-37-6 5’-azido-2’,5’-dideoxyuridine 
• 964-26-1 2'-deoxyuridine-5'-monophosphate 
• 27999-47-9 ((2R,3S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-hydroxytetrahydrofuran-2-yl)methyl 4-methylbenzenesulfonate 
• 951-78-0 2'-deoxyuridine 

Downstream Products

• 106929-02-6 2',5'-dideoxy-5'-(4-(fluorosulfonyl)benzamido)uridine 
• 66-22-8 uracil 
• 1340593-25-0 5'-(bis(4-fluorophenyl)methylamino)-2',5'-dideoxyuridine 
• 859206-73-8 5'-(4-methoxytrityl)amino-2',5'-dideoxyuridine 
• 859206-63-6 5'-[diphenyl(4-pyridyl)methyl]amino-2',5'-dideoxyuridine 
• 859206-74-9 5'-(2-chlorotrityl)amino-2',5'-dideoxyuridine 
• 1277164-76-7 5'-[diphenyl-(5-pyrimidyl)methyl]amino-2',5'-dideoxyuridine 
• 1327273-80-2 UDP-5''-amino-2'',5''-dideoxy-α-D-ribose 
• 58-98-0 UDP 
• 56045-73-9 AIdUrd 
• 864948-86-7 [(2R,3S,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-3-hydroxy-tetrahydro-furan-2-ylmethyl]-phosphoramidic acid diphenyl ester 
• 859206-66-9 1-{(2R,4S,5R)-4-Hydroxy-5-[(trityl-amino)-methyl]-tetrahydro-furan-2-yl}-1H-pyrimidine-2,4-dione 

Relevant articles and documents

Norepinephrine-Transporter-Targeted and DNA-Co-Targeted Theranostic Guanidines

High risk neuroblastoma often recurs, even with aggressive treatments. Clinical evidence suggests that proliferative activities are predictive of poor outcomes. This report describes syntheses, characterization, and biological properties of theranostic guanidines that target norepinephrine transporter and undergo intracellular processing, and subsequently their catabolites are efficiently incorporated into DNA of proliferating neuroblastoma cells. Radioactive guanidines are synthesized from 5-radioiodo-2′-deoxyuridine, a molecular radiotherapy platform with clinically proven minimal toxicities and DNA-targeting properties. The transport of radioactive guanidines into neuroblastoma cells is active as indicated by the competitive suppression of cellular uptake by meta-iodobenzylguanidine. The rate of intracellular processing and DNA uptake is influenced by the agent's catabolic stability and cell population doubling times. The radiotoxicity is directly proportional to DNA uptake and duration of exposure. Biodistribution of 5-[125I]iodo-3′-O-(?-guanidinohexanoyl)-2′-deoxyuridine in a mouse neuroblastoma model shows significant tumor retention of radioactivity. Neuroblastoma xenografts regress in response to the clinically achievable doses of this agent.

Functionalized C-nucleosides as remarkable RNA binders: Targeting of prokaryotic ribosomal A-site RNA

RNA represents an extremely promising and yet challenging therapeutic target. Here, we report the design of a series of C-nucleosides as original RNA binders. Some of them bind strongly and selectively to A-site prokaryotic ribosomal RNA.

MIBG ANALOGS AND USES THEREOF

Compounds and compositions for targeting cells expressing norepinephrine transporter, and methods of making and using the same. The compounds comprise MIBG analogs conjugated to active agents for treatment and/or diagnosis of various conditions, including neuroblastoma.